Oculis (OCS) Stock Drops After DIAMOND Phase 3 MissThe neuro-ophthalmology and ophthalmology-focused company reported that the primary endpoint of the DIAMOND trials was not met, which has led to the decision not to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema.Despite a well-tolerated safety profile, the lack of significant improvement in visual acuity has raised concerns among investors.Riad Sherif, CEO of Oculis, said: “We are naturally disappointed that the substantial and sustained reduction in retinal thickness observed across both trials didn’t translate into BCVA improvement at week 52.”OCS Technical Analysis: Trading Below Key Moving AveragesThe stock’s current price of $14.39 is significantly below its moving averages, with the 20-day simple moving average (SMA) at $29.40, indicating it is 50.7% below this level.The moving average convergence divergence (MACD) is below its signal line, suggesting that upside momentum is fading, which could lead to further downward pressure unless a reversal occurs.Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $52.50. Recent analyst moves include:
Guggenheim: Initiated with Buy (Forecast $75.00) (May 21)
